5-Fluorouracil (5-FU) Toxicity and Chemotherapeutic Response, 5 Mutations
5-Fluorouracil (5-FU) is a thymidylate synthetase (TYMS) inhibitor widely used as a chemotherapeutic agent used systemically to treat several cancers including those of the esophagus, pancreas, stomach, breast and colorectal adenocarcinoma. It may also be used topically for basal cell carcinoma and actinic keratosis. The expression of TYMS is greater in rapidly proliferating cells like cancer cells. When systemically administered 80-85% of 5-FU is inactivated by dihydropyrimidine dehydrogenase (DPYD) into dihydro 5-FU and excreted in the urine.
Approximately 10 – 40% of patients receiving 5-FU develop severe toxicity such as neutropenia, nausea, vomiting, severe diarrhea, stomatitis, mucositis, hand-foot syndrome, and neuropathy. Germline variants on the DPYD gene (chromosome 1p21.3) can reduce the catabolism of 5-FU and are associated with increased risk of various adverse and potentially toxic complications. Therefore, it has been suggested that molecular analysis of a patients DPYD genes be performed prior to administering 5-FU systemically. However, because the frequency of deleterious variants of DYPD is low and that patients lacking such variants can still suffer grade 3 or 4 toxicity, in clinical practice such testing is rarely performed.
More than 13 variants alleles of DPYD have been reported. The most common variant is DPYD *2 (c.1905+ 1G> A, rs3918290), which results in the skipping of exon 14, a 165 base pair segment encoding amino acid residues 581 to 635 of the DPYD protein. Other common variants include c.1679T>G and c.2846A>T. The homozygous DPYD gene variants are associated with deficiency of dihydropyrimidine dehydrogenase, therefore, substitution of 5-FU with other chemotherapeutic agent is recommended. Whereas the heterozygous DPYD gene variants are associated with 30-70% reduction in the activity of dihydropyrimidine dehydrogenase, therefore, 50% reduction of standard 5-FU dose is recommended.
Germline variants in 5’-promoter enhancer region (5’-TSER) and 3’-untranslated region (3’-UTR) of the TYMS gene have been reported that can alter the 5-FU metabolism by changing the TYMS expression level and are correlated with responsiveness to 5-FU therapy.
- Useful to predict the responsiveness of 5-FU therapy
- Useful to identify individuals at risk of toxicity of 5-FU and capecitabine therapy
- DPYD gene variants may indicate a decrease in dihydropyrimidine dehydrogenase activity and are associated with increased risk of 5-FU toxicity
- Positive TYMS gene variants may predict survival of patients with colorectal adenocarcinoma receiving 5-FU therapy. Some TYMS genotypes may predict the risk of 5-FU toxicity
Negative for mutations analyzed
Whole blood (EDTA, ACD), buccal swab.
Stability
- Ambient: 72 hours
- Refrigerated: 1 week
- Frozen: unacceptable
- Clin Pharmacol Ther 2013;94:640–5 [PMID:23988873]
- Cancer Chemother Pharmacol 2007;60:503–7 [PMID:17165084]
- Mol Cancer Ther 2006;5:2895–904 [PMID:17121937]
- Clin Cancer Res 2003;9:4363–7 [PMID:14555507]
- Nat Rev Cancer 2003;3:330-8 [PMID:12724731]
- Hum Genet 1999;104: 1–9 [PMID:10071185]